Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research, development, manufacturing, and commercialization of biopharmaceutical products and medical devices in Mainland China and internationally. The company offers Guyoudao, a bone repair material; Jilifen, a human granulocyte colony stimulating factor injection; Jijufen, a human interleukin-11 injection; Jiouting, a palonosetron hydrochloride injection; Jifuwei, a fulvestrant injection; Jitansu, a fosaprepitant dimeglumine injection; and Jixinfen, PEG-G"CSF injection. It also provides Jilixin avatrombopag maleate tablets; Jipailin, a low molecular weight heparin sodium injection; and Yinuojia, an enoxaparin sodium injection. The company was formerly known as Hangzhou Jiuyuan Gene Engineering Co., Ltd. and changed its name to Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. in April 2025. Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. was incorporated in 1993 and is headquartered in Hangzhou, China.
Frequently asked questions
What sector does Hangzhou Jiuyuan Gene (2566) operate in?
Hangzhou Jiuyuan Gene belongs to the Other sector and operates in the Biotechnology industry.
What is Hangzhou Jiuyuan Gene (2566) current stock price?
As of the latest data, Hangzhou Jiuyuan Gene stock price is HK$5.70, with a previous close of HK$5.70.
What is Hangzhou Jiuyuan Gene (2566) current market capitalization?
Hangzhou Jiuyuan Gene market cap is approximately 1.37 billion.
Does Hangzhou Jiuyuan Gene (2566) pay dividends?
Yes. Hangzhou Jiuyuan Gene pays annual dividends with an annualized yield of 1.15% and an estimated annual payout of HK$0.07 per share.
When is the next ex-dividend date for Hangzhou Jiuyuan Gene (2566)?
The next ex-dividend date is scheduled for June 17, 2027.
What is Hangzhou Jiuyuan Gene (2566) beta (volatility) score?
Hangzhou Jiuyuan Gene has a beta of 0.123, indicating lower volatility than the overall market.
